Navigation Links
Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
Date:3/25/2011

ual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, ; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Fentora® is a registered trademark of Cima Labs, Inc., a subsidiary of Cephalon, Inc..

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:
Patty Eisenhaur
Watson Pharmaceuticals, Inc.
(973) 355-8141

Media:
Charlie Mayr
Watson Pharmaceuticals, Inc.
(973) 355-8483


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cephalon Wins FENTORA Patent Suit Against Watson
2. Watson Launches Generic Famvir®
3. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
4. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
5. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
6. Watson to Present at the Barclays 2011 Global Healthcare Conference
7. Watson to Present at the Cowen & Company 31st Annual Healthcare Conference
8. Watson to Present at the 2011 Citi Global Healthcare Conference
9. Watson Fourth Quarter 2010 Net Revenue Increases 21% to $953 Million
10. Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
11. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... , Dec. 17, 2014  RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today announced completion of enrollment in its first Phase ... 3-month observations confirmed the 1-month findings that were ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
... 4, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... Recent Advances in Isis, Development PipelineWhen: , Thursday, ... 9:00 a.m. PTWhere: , www.isispharm.comHow: , Live on ... listed above. Contacts: , Kristina LemonidisDirector, Investor Relations(760) ...
Cached Medicine Technology:Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... Expectant parents should leave prenatal picture-taking to medical professionals, ... of ultrasound imaging and heartbeat monitors to get "keepsake" ... warns. "Although there is a lack of ... heartbeat monitors, prudent use of these devices by trained ... biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
(Date:12/15/2014)... South Florida’s leading urgent care provider, ... a daze of hassle, hustle, and bustle that can cause ... to burns when making special meals and heartburn after eating ... at any time. To prevent this season of joy from ... list of helpful and healthful holiday tips to keep the ...
(Date:12/15/2014)... (HealthDay News) -- Expert pilots process visual information more ... make better decisions during landings, a new study shows. ... for pilots to master, and 36 percent of all ... during final approach and landing. Researchers monitored the ... experienced pilots while they were at the controls of ...
Breaking Medicine News(10 mins):Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2
... increasing aging population, it is projected by the U.S. Census Bureau ... double to more than 70 million in the U.S. alone, and ... one-third of women will experience at least one disorder of the ... & Infants Hospital has teamed up with practitioners across the state ...
... psychopathic behavior is similar to that of a person with ... similar forms of treatment," said Dr. Simone Shamay-Tsoory, who conducted ... empathy, just like patients who have suffered frontal head injury. ... University of Haifa. "Our findings show that people who have ...
... saved $77 million in 2006 if it had ... drugs angiotensin receptor blockers without a negative impact ... in CMAJ (Canadian Medical Association Journal) (pre-embargo link ... in Canada increased by more than 200% from ...
... in Medicine , the official journal of the American ... by Tufts University faculty calling for a moderate, strategic ... curricula. For 16 months, a multi-disciplinary group ... regarding personalized genomic testing at Tufts University School of ...
... News) -- Many middle-aged women could significantly reduce their risk ... High systolic blood pressure (the pressure when the heart ... its common outcomes -- heart attack, heart failure and stroke ... to the report released Jan. 24 in the journal ...
... 24, 2011) - Linda J. Van Eldik, director of the ... a $750,000 grant to further her research into a possible ... N. And Della L. Thome Memorial Foundation, and was one ... to be given in the U.S. in 2010. Van ...
Cached Medicine News:Health News:Women & Infants launches Rhode Island Network for Pelvic Floor Disorders 2Health News:A psychopath lacks empathy just like a person with frontal head injury 2Health News:Controlling the rising costs of cardiovascular care 2Health News:Tufts University calls for moderate approach to teaching personalized genomic testing 2Health News:Lowering BP Can Help Cut Women's Heart Disease Risk 2
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
Medicine Products: